Cantor Fitzgerald Reaffirms “Buy” Rating for Zimmer Biomet (ZBH)

Zimmer Biomet (NYSE:ZBH)‘s stock had its “buy” rating restated by analysts at Cantor Fitzgerald in a research report issued on Monday. They presently have a $140.00 price target on the medical equipment provider’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 10.38% from the company’s current price. Cantor Fitzgerald also issued estimates for Zimmer Biomet’s FY2018 earnings at $7.68 EPS.

The analysts wrote, “ZBH received FDA clearance for its Persona cementless knee, earlier than we expected.””

Several other equities research analysts have also commented on ZBH. SunTrust Banks set a $136.00 price objective on shares of Zimmer Biomet and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Piper Jaffray Companies lowered shares of Zimmer Biomet from an “overweight” rating to a “neutral” rating in a research report on Thursday, November 2nd. BMO Capital Markets decreased their price objective on shares of Zimmer Biomet from $140.00 to $135.00 and set an “outperform” rating on the stock in a research report on Thursday, November 2nd. Morgan Stanley decreased their price objective on shares of Zimmer Biomet from $146.00 to $136.00 and set an “overweight” rating on the stock in a research report on Thursday, November 2nd. Finally, Jefferies Group reiterated a “buy” rating and issued a $136.00 price objective on shares of Zimmer Biomet in a research report on Friday, November 3rd. Two research analysts have rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $141.67.

Zimmer Biomet (NYSE ZBH) traded up $1.05 during trading on Monday, hitting $126.84. 418,917 shares of the company traded hands, compared to its average volume of 1,465,581. Zimmer Biomet has a 1-year low of $108.03 and a 1-year high of $133.49. The company has a quick ratio of 0.83, a current ratio of 1.52 and a debt-to-equity ratio of 0.76. The stock has a market cap of $25,470.00, a price-to-earnings ratio of 14.10, a PEG ratio of 2.20 and a beta of 1.08.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Tuesday, January 30th. The medical equipment provider reported $2.10 EPS for the quarter, hitting the consensus estimate of $2.10. Zimmer Biomet had a net margin of 23.51% and a return on equity of 15.45%. The business had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.03 billion. During the same period in the previous year, the firm earned $2.14 EPS. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. research analysts forecast that Zimmer Biomet will post 7.84 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the business. Private Advisor Group LLC increased its stake in shares of Zimmer Biomet by 18.6% during the 3rd quarter. Private Advisor Group LLC now owns 6,733 shares of the medical equipment provider’s stock valued at $791,000 after acquiring an additional 1,057 shares during the last quarter. Ingalls & Snyder LLC increased its stake in shares of Zimmer Biomet by 2.6% during the 3rd quarter. Ingalls & Snyder LLC now owns 19,675 shares of the medical equipment provider’s stock valued at $2,304,000 after acquiring an additional 507 shares during the last quarter. Koch Industries Inc. increased its stake in shares of Zimmer Biomet by 49,697.3% during the 2nd quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock valued at $1,033,000 after acquiring an additional 1,038,674 shares during the last quarter. Jana Partners LLC increased its stake in shares of Zimmer Biomet by 16.6% during the 3rd quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock valued at $545,932,000 after acquiring an additional 662,497 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in shares of Zimmer Biomet by 10.0% during the 3rd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 16,444 shares of the medical equipment provider’s stock valued at $1,925,000 after acquiring an additional 1,494 shares during the last quarter. Institutional investors own 86.18% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2018/02/05/cantor-fitzgerald-reaffirms-buy-rating-for-zimmer-biomet-zbh-2.html.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply